Immunocompromised Mouse
Immunocompromised Mouse - Related Videos
05:10
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
0 Views •
Cited by 5 •
2010
This protocol describes the isolation and dissociation of mouse medulloblastoma tissue, and subsequent allografting of the tumor cells into immunocompromised recipient mice in order to initiate secondary medulloblastoma.
03:40
Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
0 Views •
2023
Intrafemoral injections allow for the engraftment of a small number of hematopoietic stem and progenitor cells (HSPCs), by placing the cells directly in the bone marrow cavity. Here we describe an experimental protocol of intrafemoral injection of human HSPCs into immunodeficient mice.
09:08
Multiple-mouse Neuroanatomical Magnetic Resonance Imaging
0 Views •
Cited by 59 •
2011
Magnetic resonance imaging (MRI) has become an increasingly popular tool for examining the phenotype of genetically altered mice. This article illustrates the methods necessary to achieve high-throughput phenotyping of genetically altered mice using multiple-mouse MRI.
03:32
Patient-derived Tumor Xenografting: A Technique to Generate Experimental Mouse Model for Evaluating Urothelial Cell Carcinoma
0 Views •
2023
This video describes the procedure to generate an experimental xenograft murine model, which can be used for studying urothelial cell carcinoma progression.
03:50
Candida albicans Biofilm Formation in an In Vivo Mouse Model
0 Views •
2025
This video demonstrates the development of an in vivo mouse model to study the biofilm formation of Candida albicans in subcutaneous tissue. The experiment involves implanting Candida-infected devices in the animal's back region for biofilm development.
FAQs
The particular defect determines which rejection pathways are weakened. Loss of T-cell or B-cell function reduces adaptive immune activity, whereas disruption of innate immune pathways changes early host defenses. These differences influence whether implanted human tumors establish and how closely tumor behavior reflects interactions in a normal host, so model selection should match the biological question.
Reduced immune rejection allows human tumor material to establish, but it also removes or weakens normal tumor-host interactions. Consequently, growth, metastasis, and treatment responses observed in these mice may not represent the full behavior of tumors in an intact immune system. That limitation explains the value of complementary models.
Both approaches support in vivo studies of human tumors, but xenograft models use implanted human tumor cells or tissues, whereas patient-derived models retain material obtained from a patient's tumor. Each can support analyses of growth, metastasis, and therapeutic response. The choice depends on whether the study prioritizes a defined implanted tumor system or patient-linked tumor material.
Conditioning treatments provide an additional way to reduce immune rejection in selected experiments. By lowering host resistance to implanted human tumor material, they can support tumor establishment alongside the mouse's genetic immune alterations. However, conditioning is part of the experimental context, so researchers should consider its contribution when interpreting tumor growth and therapeutic response.
An experimental workflow typically begins by selecting an immune-deficient genotype and deciding whether conditioning is needed. Researchers then implant human tumor cells or tissue, evaluate tumor establishment and growth, and may assess metastasis or responses to a therapy. Keeping model selection and treatment comparisons aligned with the research question improves interpretation of results.
These models can reveal whether a candidate treatment changes tumor growth, metastatic behavior, or therapeutic response in vivo, while also supporting drug-efficacy studies. Such measurements connect an intervention to observable tumor outcomes in a living host. Researchers can use these comparisons to assess efficacy and identify results that warrant further investigation in complementary models.
Because their immune deficits can remove important components of the response being studied, immunocompromised mice may be insufficient for judging therapies that depend on immune activity. Cancer researchers therefore often complement them with humanized or immunocompetent mice. Using these models together helps address tumor-host interactions and translational relevance more fully.